Jing Zou

Title: Innovations by Jing Zou in RNA Vaccine Development

Introduction

Jing Zou is an accomplished inventor based in Galveston, TX (US). He has made significant contributions to the field of immunology, particularly in the development of vaccines targeting plus-sense single-stranded RNA viruses. His innovative work has the potential to enhance public health by providing effective immunization strategies against various viral diseases.

Latest Patents

Jing Zou holds a patent for a groundbreaking invention titled "DNA plasmid-launched live-attenuated vaccines for plus-sense single-stranded RNA." This invention relates to the creation of immunogenic compositions that include a DNA copy of at least one live attenuated plus-sense single-stranded RNA virus genome. Notably, it encompasses the genomes of live-attenuated Zika virus (ZIKV), Japanese encephalitis virus (JEV), and yellow fever virus (YFV). The immunogenic compositions developed through this patent can be utilized for treating or conferring protective immunity against diseases associated with plus-sense single-stranded RNA viruses. Remarkably, protective immunity can be conferred at low doses, as low as 300 or 500 ng after the administration of a single plasmid-launched vaccine dosage.

Career Highlights

Jing Zou is affiliated with the University of Texas System, where he continues to advance his research in vaccine development. His work is characterized by a commitment to innovation and a focus on addressing critical health challenges posed by viral infections.

Collaborations

Jing Zou collaborates with esteemed colleagues, including Xuping Xie and Pei-Yong Shi, who contribute to the research and development efforts in the field of RNA vaccines.

Conclusion

Jing Zou's contributions to the development of RNA vaccines represent a significant advancement in immunology. His innovative approach to creating effective immunogenic compositions has the potential to improve public health outcomes and provide lasting protection against viral diseases.